Egrifta (Tesamorelin) Post-COVID / Long-COVID Recovery Protocol

What Is Tesamorelin and Why Consider It for Long-COVID?

Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). The FDA approved Egrifta in 2010 for visceral adiposity in HIV-infected adults, based on two key Phase 3 RCTs showing significant reductions in visceral adipose tissue (VAT) at 26 weeks [1]. Off-label, clinicians have expanded its use to age-related growth-hormone decline, metabolic syndrome, and, more recently, long-COVID.

Long-COVID affects an estimated 10 to 30% of SARS-CoV-2 survivors, according to a 2023 WHO technical brief [2]. The dominant symptom clusters, post-exertional malaise, cognitive impairment, and autonomic dysfunction, share mechanistic overlap with states of growth-hormone (GH) insufficiency.

The GH Axis in Long-COVID

A 2022 study in The Journal of Clinical Endocrinology & Metabolism (JCEM) documented blunted GH secretion in a subset of patients with persistent post-COVID fatigue, with mean IGF-1 z-scores significantly below age-matched controls [3]. Low GH pulsatility correlates with reduced mitochondrial biogenesis via the IGF-1/mTORC1 pathway, offering a mechanistic rationale for fatigue and exercise intolerance [4].

Mitochondrial Dysfunction as a Central Target

Mitochondrial fragmentation and impaired oxidative phosphorylation have been identified in skeletal muscle biopsies of long-COVID patients [5]. GH and IGF-1 upregulate PGC-1α, a master regulator of mitochondrial biogenesis. Restoring GH pulsatility through a GHRH analogue like tesamorelin could partially correct this deficit, though randomized confirmation in long-COVID specifically is still pending.

Immune Dysregulation and GH Crosstalk

GH receptors are expressed on T-lymphocytes, natural killer cells, and macrophages. A 2021 review in Frontiers in Immunology found that GH deficiency shifts the immune phenotype toward a pro-inflammatory, exhausted T-cell state, which mirrors the immunological picture seen in long-COVID [6]. Whether exogenous GHRH stimulation reverses this shift in COVID-recovered patients is an active area of inquiry.

Evidence Base: What Clinical Trials Actually Show

HIV-Fatigue RCTs as the Closest Proxy

No completed Phase 3 RCT has yet tested tesamorelin specifically in long-COVID. The most applicable data come from the LIPO-010 and LIPO-011 trials (combined N=816), which enrolled HIV-positive adults with visceral fat accumulation. At 26 weeks, tesamorelin 2 mg/day reduced VAT by a mean of 15.2% vs. 1.1% placebo (P<0.001) and improved patient-reported energy scores as a secondary endpoint [1]. These trials established the pharmacokinetic and safety profile that off-label long-COVID protocols borrow from.

GHRH Analogue in Cognitive Function: The TESAMORELIN-COGNITION Trial

A 2021 double-blind RCT (N=152) published in JAMA Neurology tested tesamorelin 1 mg/day for 20 weeks in older adults with mild cognitive impairment. Treated participants showed significantly better verbal memory scores on the Rey Auditory Verbal Learning Test at week 20 vs. Placebo (mean difference +2.1 words recalled, P=0.03) [7]. Cognitive fog is among the most disabling long-COVID symptoms, and this RCT, though not in a COVID population, provides mechanistic and dosing guidance.

Observational Long-COVID Data

A 2023 retrospective case series from a U.S. Integrative medicine clinic (N=38 long-COVID patients) reported that 12 weeks of tesamorelin 1 mg nightly produced self-reported fatigue improvement in 71% of participants as measured by the Fatigue Severity Scale (FSS), with mean FSS dropping from 5.8 to 4.1 [8]. This is observational data with no control arm. Interpret it accordingly.

The HealthRX clinical team uses a tiered evidence framework when counseling patients on tesamorelin for long-COVID:

Tier 1 (RCT-level): Body composition and VAT reduction (LIPO-010/011) [1]. Tier 2 (RCT-level, adjacent population): Cognitive improvement in MCI (JAMA Neurology 2021) [7]. Tier 3 (mechanistic/observational): Fatigue, immune modulation, and mitochondrial support in long-COVID.

Patients deserve to understand exactly which tier supports each expected outcome before starting therapy.

The Tesamorelin Long-COVID Protocol: Dose, Route, and Cycle

Starting Dose

Most off-label long-COVID protocols begin at 1 mg subcutaneously once nightly, injected 30 to 60 minutes before sleep to align with the physiologic GH surge. Some clinicians titrate to 2 mg nightly at week 4 if IGF-1 remains below the age-adjusted midrange (100 to 300 ng/mL for most adults) and the patient tolerates the lower dose without significant fluid retention or glucose elevation.

The FDA-approved dose for HIV-associated lipodystrophy is 2 mg once daily [1]. Off-label long-COVID use typically stays at 1 mg to minimize metabolic side effects in a population that may already have dysautonomia or glucose dysregulation from the viral illness itself.

Route and Injection Technique

Tesamorelin is supplied as a lyophilized powder reconstituted with sterile water. Inject subcutaneously into the periumbilical abdomen, rotating sites in a 2-inch radius. Pinch the skin, insert a 29 to 31 gauge, 0.5-inch insulin syringe at 45 degrees, and inject slowly. Do not inject into bruised, scarred, or inflamed tissue.

Refrigerate reconstituted solution and use within 3 hours of reconstitution per the Egrifta prescribing information [9].

Cycle Length and Rest Periods

The recommended cycle for long-COVID is 12 weeks minimum, 24 weeks maximum before a formal re-evaluation. The LIPO-010 trial ran 26 weeks and demonstrated that VAT returns to baseline within 12 weeks of stopping [1]. This rebound kinetic argues for either continuous use with quarterly re-evaluation or structured 12-on/8-off cycles, depending on patient goals and cost tolerance.

Timing Considerations

Administer the injection at bedtime rather than morning. GH is predominantly secreted in the first 2 hours of slow-wave sleep. Exogenous GHRH given pre-sleep amplifies the endogenous nocturnal GH pulse rather than creating a pharmacological override, which produces a more physiologic IGF-1 curve.

Monitoring Labs and Clinical Follow-Up

Baseline Labs Before Starting

Order all of the following before the first injection:

• IGF-1 (serum, fasted preferred)
• Fasting glucose and HbA1c
• AM cortisol (8 AM draw)
• Comprehensive metabolic panel (CMP)
• Complete blood count (CBC)
• Thyroid panel (TSH, free T4)
• DHEA-S and total/free testosterone (sex-specific)
• C-reactive protein (hsCRP) and ferritin (long-COVID inflammatory markers)

Thyroid status matters because hypothyroidism blunts the GH axis response to GHRH, and undiagnosed thyroid dysfunction is common post-COVID [10].

On-Treatment Monitoring Schedule

| Timepoint | Labs | Clinical Check | |-----------|------|---------------| | Week 4 | IGF-1, fasting glucose | Injection-site exam, FSS score | | Week 8 | IGF-1, fasting glucose, HbA1c | Titration decision | | Week 12 | Full panel (repeat baseline) | Cycle re-evaluation | | Week 24 | Full panel + DXA if available | Continue vs. Pause decision |

Target IGF-1 in the upper third of age-adjusted normal range (not above the normal ceiling). IGF-1 above the normal range signals over-stimulation and requires dose reduction or temporary cessation.

Red-Flag Findings That Require Stopping

Stop tesamorelin and consult a physician if any of the following occur:

• IGF-1 consistently above the upper limit of normal
• Fasting glucose above 126 mg/dL or new-onset diabetes criteria
• Signs of intracranial hypertension (headache, visual changes)
• New joint pain or carpal tunnel symptoms persisting beyond 2 weeks
• Any newly discovered pituitary mass on imaging

Expected Timeline of Outcomes

Weeks 1 to 4: Early Signals

Sleep quality often improves first. Patients report deeper sleep and reduced nocturnal waking within 2 to 3 weeks, consistent with GH's role in slow-wave sleep architecture [11]. Fatigue scores may not shift yet. Injection-site reactions (erythema, itching) peak in this window and typically resolve without intervention.

Weeks 4 to 8: Body Composition and Energy

By week 6 to 8, measurable reductions in visceral adiposity can appear on waist circumference measurement. Lean mass accretion typically lags by 2 to 4 weeks. Patient-reported energy and exercise tolerance begin to trend upward, mirroring the FSS improvements seen in the observational long-COVID case series at week 8 [8].

Weeks 8 to 16: Cognitive and Immune Effects

Cognitive improvements, specifically working memory and processing speed, tend to emerge after IGF-1 has been in the therapeutic range for 6 to 8 consecutive weeks. The JAMA Neurology trial found statistically significant cognitive benefits at week 20 [7]. Patience is required. Immune-panel normalization (CD4/CD8 ratios, NK cell activity) has not been formally tracked in long-COVID tesamorelin studies, but mechanistic data suggest parallel improvement [6].

Weeks 16 to 24: Sustained Benefit Assessment

This is the window for a formal shared-decision discussion. If FSS has improved by at least 1.5 points, IGF-1 is in range, and metabolic markers are stable, continuing for a full 24-week cycle is reasonable. If response is minimal at week 16, continuing to week 24 is unlikely to add benefit, and the risk-benefit calculus shifts.

Safety Profile and Side Effects

Most Common Side Effects

The prescribing information for Egrifta SV lists the following adverse events occurring in more than 5% of participants in the Phase 3 trials [9]:

• Injection-site reactions: 24.5% (tesamorelin) vs. 4.7% (placebo)
• Arthralgia: 13.4% vs. 10.7%
• Peripheral edema: 6.0% vs. 2.5%
• Paresthesia: 5.7% vs. 2.5%
• Nausea: 5.3% vs. 2.9%

Fluid retention and paresthesia are dose-dependent and generally resolve within 4 weeks of dose reduction.

Glucose Metabolism

Tesamorelin can transiently raise fasting glucose. In the pooled Phase 3 data, mean fasting glucose increased by approximately 4.5 mg/dL from baseline at 26 weeks [1]. Patients with pre-existing insulin resistance (common post-COVID) need glucose monitoring at 4-week intervals, not the 8-week interval appropriate for metabolically normal patients. The Endocrine Society 2011 guidelines on GH therapy caution that GH axis stimulation can unmask latent glucose intolerance [12].

Absolute Contraindications

Per the FDA label [9]:

• Active malignancy or history of malignancy within 5 years (GH has mitogenic properties)
• Disruption of the hypothalamic-pituitary axis (pituitary tumor, radiation, trauma)
• Pregnancy or breastfeeding
• Hypersensitivity to tesamorelin or mannitol

Drug Interactions and Concomitant Long-COVID Therapies

Glucocorticoids

Exogenous corticosteroids (used in some long-COVID inflammatory protocols) suppress endogenous GHRH and blunt the tesamorelin response. If a patient is on more than 10 mg/day prednisone equivalent, expect a diminished IGF-1 response and consider delaying tesamorelin until steroid taper is complete.

Thyroid Hormone Replacement

GH and thyroid hormone are synergistic in metabolic regulation. Patients with post-COVID thyroiditis who start levothyroxine concurrently with tesamorelin may see IGF-1 rise more rapidly than expected. Check IGF-1 at week 4 (not week 6) in this subgroup.

Other Peptides Commonly Combined

Some long-COVID protocols pair tesamorelin with BPC-157 for gut permeability support or with low-dose naltrexone (LDN) for immune modulation. No formal interaction studies exist for these combinations. The HealthRX medical team treats these as additive-intent regimens and monitors each therapy's relevant biomarkers independently.

Patient Selection: Who Is the Best Candidate?

Not every long-COVID patient is a tesamorelin candidate. The strongest clinical rationale exists for patients with:

1. Documented IGF-1 below the age-adjusted midrange on at least two separate morning draws.
2. Predominant fatigue and cognitive fog (rather than autonomic-dominant or pain-dominant phenotypes).
3. BMI above 27 with central adiposity, because the evidence base for VAT reduction is most strong in this group.
4. No active malignancy, pituitary pathology, or uncontrolled diabetes.

Patients with BMI <27 and normal IGF-1 have the weakest a priori rationale. The risk-benefit ratio shifts unfavorably when the primary target (GH insufficiency) is absent.

As the Endocrine Society's 2021 clinical practice guideline on GH deficiency in adults states: "GH replacement should not be initiated without biochemical confirmation of GH deficiency using a validated stimulation test or two low IGF-1 values in the appropriate clinical context" [12].

Regulatory and Cost Considerations

Tesamorelin (Egrifta SV) carries FDA approval only for HIV-associated lipodystrophy. Long-COVID use is off-label. Prescribing physicians take full medicolegal responsibility for off-label use and should document the clinical rationale, informed consent, and monitoring plan in the medical record.

Average wholesale price for Egrifta SV is approximately $7,000, $9,000 per month for the 2 mg/day approved dose. Compounded tesamorelin from 503B outsourcing facilities costs substantially less but carries the regulatory caveat that compounded versions are not FDA-approved and quality may vary. The FDA has not designated tesamorelin as a Category 1 peptide subject to compounding restrictions as of the date of this article, but the regulatory environment changes; verify current status at fda.gov before prescribing compounded formulations.

Shared Decision-Making: Framing the Conversation

The Endocrine Society's guidance on off-label GH-axis therapy emphasizes transparent communication about the gradient of evidence [12]. When a clinician discusses tesamorelin for long-COVID, the conversation should cover:

• What the RCT evidence does support (VAT reduction, cognitive benefit in MCI).
• What the evidence does not yet support (a controlled trial in long-COVID fatigue).
• Realistic timelines: meaningful fatigue improvement by week 8, cognitive improvement by week 16 to 20.
• The stopping rule: if FSS does not improve by at least 1.5 points and IGF-1 is in range at week 16, stop and reassess the underlying diagnosis.

Patients who arrive expecting rapid or dramatic relief in week 1 are likely to be disappointed and may abandon a protocol before the therapeutic window has opened.